This study investigated the role played by HIF-1α activity in the susceptibility of GBMs to TMZ treatment, and its role as an early biomarker of tumor response to this drug and has led to us proposing that CMA is the mechanism responsible for modulating such activity. Here, HIF1A is linked to neoplasm.